DexCom, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
252131107
SEDOL
BM9CB52
CIK
0001093557
www.dexcom.com
LEI:
©
FIGI: BBG000QTF8K1
DXCM
DexCom, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Medical Devices
AI
PROFILER
NAME
DexCom, Inc.
ISIN
US2521311074
TICKER
DXCM
MIC
XNAS
REUTERS
DXCM.OQ
BLOOMBERG
DXCM US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
TradingView ActivTrader MT4 MT5
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Sat, 21.12.2024       DexCom
US2521311074

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into DexCom, Inc. (“DexCom” or the “Company”) (NasdaqGS: DXCM). On July 25, 2024, the Company announced its financial results for the second quarter of fiscal 2024, d...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Tue, 17.12.2024       DexCom
US2521311074

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Tue, 17.12.2024       DexCom
US2521311074

Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older. This press relea...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Tue, 19.11.2024       DexCom
US2521311074

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, and ŌURA, maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. Combi...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Thu, 14.11.2024       DexCom
US2521311074

This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first step to discover what they’re made of. This comes as global data1 shows nearly 70% of people with diabetes say they didn’t know where to begin their health journey when they were f...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Thu, 24.10.2024       DexCom
US2521311074

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis. U.S. revenue declined 2% and international revenue grew 12% on a reported...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Mon, 21.10.2024       DexCom
US2521311074

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ:DXCM) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faru...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Fri, 18.10.2024       DexCom
US2521311074

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024. DexCom describes itself as an “international company that develops, manufactures, and distributes continuous glucose monitoring syst...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Thu, 17.10.2024       DexCom
US2521311074

The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”). If you are a shareho...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
Tue, 15.10.2024       DexCom
US2521311074

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between April 28, 2023 and July 25, 2024, inclusive (the “Class Period”) The lead p...
Read More
DexCom
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S